carbamates and binimetinib

carbamates has been researched along with binimetinib in 64 studies

Research

Studies (64)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's28 (43.75)24.3611
2020's36 (56.25)2.80

Authors

AuthorsStudies
Dummer, R; Galliker, NA; Goldinger, SM; Kamarashev, J; Murer, C1
Beasley, G; Rossfeld, K; Salama, AK; Turner, MC; Tyler, D1
Daud, A; Tsai, K1
Frimat, M; Gnemmi, V; Hazzan, M; Lionet, A; Maanaoui, M; Noël, C; Provot, F; Saint-Jacques, C1
Flaherty, K1
Alaibac, M; Chiarion Sileni, V; Frigo, AC; Russo, I; Zorzetto, L1
Grob, JJ1
Arance, A; Ascierto, PA; Chiarion-Sileni, V; de Groot, JWB; Dummer, R; Dutriaux, C; Flaherty, KT; Garbe, C; Gogas, HJ; Gutzmer, R; Krajsova, I; Liszkay, G; Loquai, C; Mandala, M; Moutouh-de Parseval, LA; Pickard, MD; Robert, C; Sandor, V; Schadendorf, D; Yamazaki, N1
Sidaway, P1
Shirley, M1
Anastasopoulou, A; Diamantopoulos, PT; Gogas, H; Papaxoinis, G; Stoungioti, S1
Martin-Liberal, J1
Arance, A; Ascierto, PA; Chiarion Sileni, V; de Groot, JWB; Dummer, R; Dutriaux, C; Flaherty, KT; Garbe, C; Gogas, HJ; Gutzmer, R; Krajsova, I; Liszkay, G; Loquai, C; Mandala, M; Moutouh-de Parseval, LA; Pickard, MD; Robert, C; Sandor, V; Schadendorf, D; Yamazaki, N1
Burton, NC; Cyran, CC; Eschbach, RS; Heimer, M; Hirner-Eppeneder, H; Kazmierczak, PM; Keinrath, G; Reiser, MF; Ricke, J; Schneider, MJ; Solyanik, O; Todica, A1
Barysch, M; Cheng, PF; Conrad, S; Dummer, R; Galliker, N; Goldinger, SM; Graf, NP; Koelblinger, P; Mangana, J1
Robert, C1
Ascierto, PA; Festino, L; Trojaniello, C; Vanella, V1
Christy-Bittel, J; Ciardiello, F; Cuyle, PJ; Desai, J; Elez, E; Fakih, M; Gollerkeri, A; Grothey, A; Huijberts, S; Kopetz, S; Maharry, K; Montagut, C; Peeters, M; Sandor, V; Schellens, JHM; Tabernero, J; Van Cutsem, E; Wasan, H; Yaeger, R; Yoshino, T1
Livingstone, E1
Rose, AAN1
Arance, A; Ascierto, PA; de Groot, JWB; Dummer, R; Dutriaux, C; Flaherty, KT; Garbe, C; Gogas, HJ; Gollerkeri, A; Gutzmer, R; Krajsova, I; Liszkay, G; Loquai, C; Mandala, M; Pickard, MD; Robert, C; Schadendorf, D; Sileni, VC; Yamazaki, N1
Assi, T; Farhat, F; Kattan, C; Kattan, J1
Bycroft, R; Ngo, P1
Anderson, L; Arkenau, HT; Braun, M; Calvo Ferrandiz, A; Christy-Bittel, J; Ciardiello, F; Dekervel, J; Desai, J; Elez, E; Garcia-Alfonso, P; Gollerkeri, A; Grothey, A; Guo, C; Guren, TK; Hong, YS; Keir, C; Kim, TW; Kopetz, S; Krishnan, A; Lonardi, S; Loupakis, F; Maharry, K; Morris, V; Orlov, S; Pfeiffer, P; Pickard, M; Sandor, V; Schellens, JHM; Steeghs, N; Tabernero, J; Tarpgaard, LS; Van Cutsem, E; Wasan, H; Yaeger, R; Yoshino, T1
Killock, D1
Gunjur, A1
Amaria, RN; Amin, A; Davies, MA; Davis, JM; Diab, A; Glitza, IC; Holbrook, K; Lutzky, J; Patel, SP; Tawbi, H1
Fadul, CE; Gentzler, RD; Hall, RD; McLoughlin, EM; Patel, SH1
Carr, MJ; Eroglu, Z; Sun, J; Zager, JS1
Chandrasekharan, C; Kamatham, S; Kasi, PM; Shahjehan, F1
Arance, A; Ascierto, PA; de Groot, JWB; Dummer, R; Flaherty, KT; Garbe, C; Gogas, HJ; Gollerkeri, A; Gutzmer, R; Krajsova, I; Liszkay, G; Loquai, C; Mandala, M; Pickard, MD; Robert, C; Schadendorf, D1
Limmer, A; Robare, S; Swali, R1
Specenier, P1
Sharma, V; Vanidassane, I1
Prasad, V1
Pietrantonio, F1
Grothey, A; Kopetz, S; Tabernero, J1
Aiba, S; Amagai, R; Fujimura, T; Hashimoto, A; Kambayashi, Y; Ohuchi, K; Sato, Y; Tanita, K1
Matsudate, Y1
Ascierto, PA; Carlino, MS; Dummer, R; Elez, E; Lebbé, C; Patel, S; Pickard, MD; Sandor, V; Siena, S; Sullivan, RJ; Tan, DSW; Weber, J; Wollenberg, L1
Forchhammer, S; Forschner, A; Garbe, C; Lang, N; Schaller, M; Schinaia, CG; Wolfsperger, F1
Leng, T; Li, AS; Liao, YJ; Nagpal, S1
Indini, A; Mandalà, M1
Byron, Y; Nott, L; Shackleton, M1
Ahlström, H; Botling, J; Dahlstrand, H; Koliadi, A; Öberg, K; Tholander, B; Ullenhag, GJ; Von Heideman, A1
Boilève, A; Samalin, E1
Aiba, S; Amagai, R; Fujimura, T; Fujisawa, Y; Furudate, S; Hashimoto, A; Ito, T; Kambayashi, Y; Kato, H; Kunimoto, K; Maekawa, T; Matsushita, S; Muto, Y; Nakamura, Y; Ohuchi, K; Yamamoto, Y; Yoshino, K1
Bernards, R; Boelens, MC; Huijberts, SCFA; Opdam, FL1
Ding, D; Hu, H; Huang, J; Li, S; Zhu, Y1
Lankheet, NAG; Meussen, E; Mian, P; Piersma, D1
Duong, JP; Gallois, C; Karras, A; Lazareth, H; Stammler, R; Taieb, J; Thervet, E1
Baric, L; Cantagrel, A; Di Palma, M; Ederhy, S; Paques, M; Perlemuter, G; Sibaud, V1
Spagnolo, F1
Al-Kindi, S; Barnholtz-Sloan, JS; de Lima, M; Dowlati, A; Fradley, MG; Guha, A; Gutierrez, JM; Jain, C; Jain, P; Lenihan, D; Oliveira, GH1
Hanft, S; Khullar, K; Mehnert, JM; Weiner, JP1
Arance, A; Ascierto, PA; Dummer, R; Dutriaux, C; Flaherty, KT; Garbe, C; Gogas, H; Gollerkeri, A; Gutzmer, R; Jan de Willem, G; Krajsová, I; Liszkay, G; Loquai, C; Mandalà, M; Murris, J; Queirolo, P; Robert, C; Schadendorf, D; Sellier, AT; Sileni, VC; Suissa, J; Yamazaki, N1
Ardizzoni, A; D'Errico, A; Di Federico, A; Gelsomino, F; Grilli, G; Salvagni, S; Tardio, ML1
Kono, M; Noto, M; Sato, T; Yamada, M1
Fakih, M; Ji, J; Wang, C1
Ascierto, PA; Brill, K; Dummer, R; McKean, M; Panella, T; Pietro, AD; Polli, A; Ribas, A; Robert, C; Santos, ES; Schadendorf, D; Sullivan, RJ1
Amano, H; Miura, S; Onishi, M; Watabe, D1
Arkenau, HT; Belani, A; Ciardiello, F; Desai, J; Garcia-Alfonso, P; Grothey, A; Guren, TK; Hong, YS; Kopetz, S; Loupakis, F; Steeghs, N; Tabernero, J; Van Cutsem, E; Wasan, H; Yaeger, R; Yoshino, T; Zhang, X1
Antista, M; Antonuzzo, L; Bensi, M; Boccaccino, A; Borelli, B; Cremolini, C; Crespi, V; Giampieri, R; Giordano, M; Intini, R; Libertini, M; Lonardi, S; Moretto, R; Noto, C; Noto, L; Parisi, A; Passardi, A; Persano, M; Puccini, A; Rihawi, K; Rossini, D; Roviello, G; Salati, M; Tamberi, S; Zichi, C1
Di Guardo, L1

Reviews

12 review(s) available for carbamates and binimetinib

ArticleYear
Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:5

    Topics: Benzamides; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Piperidines; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyridines; Skin Neoplasms; Sulfonamides; Thiazoles

2017
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    The oncologist, 2017, Volume: 22, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Carbamates; Fever; Humans; Imidazoles; Indoles; Melanoma; Mitogen-Activated Protein Kinase Kinases; Oximes; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Diseases; Sulfonamides; Vemurafenib

2017
Encorafenib and Binimetinib: First Global Approvals.
    Drugs, 2018, Volume: 78, Issue:12

    Topics: Benzimidazoles; Carbamates; Drug Approval; Humans; MAP Kinase Kinase Kinases; Melanoma; Molecular Structure; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Treatment Outcome; United States

2018
[What's new in oncodermatology?]
    Annales de dermatologie et de venereologie, 2018, Volume: 145 Suppl 7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Benzimidazoles; Biomarkers, Tumor; Carbamates; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Dermatology; Humans; Melanoma; Skin Neoplasms; Sulfonamides; Survival Analysis

2018
Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
    Expert review of clinical pharmacology, 2019, Volume: 12, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Disease-Free Survival; Humans; Melanoma; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides

2019
Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
    Drugs of today (Barcelona, Spain : 1998), 2019, Volume: 55, Issue:4

    Topics: Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides

2019
An evaluation of encorafenib for the treatment of melanoma.
    Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides

2020
Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
    Drugs of today (Barcelona, Spain : 1998), 2019, Volume: 55, Issue:11

    Topics: Benzimidazoles; Carbamates; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Humans; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Sulfonamides

2019
An overview of binimetinib for the treatment of melanoma.
    Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Clinical Trials as Topic; GTP Phosphohydrolases; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Melanoma; Membrane Proteins; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides

2020
Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients.
    Expert opinion on drug safety, 2020, Volume: 19, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Melanoma; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Survival Rate

2020
[Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].
    Bulletin du cancer, 2021, Volume: 108, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Carbamates; Drug Combinations; Humans; Imidazoles; Melanoma; Mitogen-Activated Protein Kinase Kinases; Mutation; Oximes; Piperidines; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Sulfonamides; Vemurafenib

2021
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable
    Future oncology (London, England), 2022, Volume: 18, Issue:17

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Neoplasms, Second Primary; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Skin Neoplasms; Sulfonamides

2022

Trials

10 trial(s) available for carbamates and binimetinib

ArticleYear
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carbamates; Female; Humans; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Time Factors; Vemurafenib; Young Adult

2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carbamates; Disease Progression; Female; Genetic Predisposition to Disease; Humans; Male; Melanoma; Middle Aged; Mutation; Phenotype; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Time Factors; Vemurafenib; Young Adult

2018
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 06-10, Volume: 37, Issue:17

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Folic Acid; Humans; Irinotecan; Male; Middle Aged; Mutation; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Sulfonamides; Survival Rate

2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 119

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Fatigue; Female; Humans; Incidence; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinases; Mutation; Nausea; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib; Vomiting

2019
Encorafenib, Binimetinib, and Cetuximab in
    The New England journal of medicine, 2019, 10-24, Volume: 381, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Disease Progression; Electrocorticography; Female; Humans; Intention to Treat Analysis; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides; Survival Analysis

2019
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 126

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Diarrhea; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Mutation; Nausea; Outcome Assessment, Health Care; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib; Vomiting

2020
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 10-01, Volume: 26, Issue:19

    Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides

2020
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 152

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Female; Humans; Male; Melanoma; Middle Aged; Mutation; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Quality of Life; Skin Neoplasms; Sulfonamides; Vemurafenib; Young Adult

2021
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.
    ESMO open, 2022, Volume: 7, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Mutation; Patient Reported Outcome Measures; Proto-Oncogene Proteins B-raf; Quality of Life; Sulfonamides

2022
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
    ESMO open, 2022, Volume: 7, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Sulfonamides

2022

Other Studies

42 other study(ies) available for carbamates and binimetinib

ArticleYear
Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
    European journal of dermatology : EJD, 2015, Volume: 25, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Imidazoles; Male; Melanoma; Mitogen-Activated Protein Kinases; Oximes; Panniculitis; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Neoplasms; Sulfonamides

2015
Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: A case report.
    Medicine, 2017, Volume: 96, Issue:25

    Topics: Antineoplastic Agents; Benzimidazoles; Carbamates; Female; Glomerulonephritis; Humans; Kidney; Lung Neoplasms; MAP Kinase Kinase Kinases; Melanoma; Middle Aged; Protein Kinase Inhibitors; Sulfonamides; Vasculitis

2017
In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma.
    Clinical advances in hematology & oncology : H&O, 2017, Volume: 15, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides

2017
A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
    European journal of dermatology : EJD, 2017, Oct-01, Volume: 27, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Imidazoles; Indoles; MAP Kinase Kinase Kinases; Melanoma; Melanoma, Cutaneous Malignant; Mutation; Oximes; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Diseases; Skin Neoplasms; Sulfonamides; Vemurafenib

2017
Is there any interest in a new BRAF-MEK inhibitor combination in melanoma?
    The Lancet. Oncology, 2018, Volume: 19, Issue:5

    Topics: Benzimidazoles; Carbamates; Humans; Melanoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib

2018
Encorafenib - a new agent for advanced-stage disease.
    Nature reviews. Clinical oncology, 2018, Volume: 15, Issue:6

    Topics: Benzimidazoles; Carbamates; Humans; Melanoma; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib

2018
Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.
    Melanoma research, 2018, Volume: 28, Issue:6

    Topics: Aged, 80 and over; Benzimidazoles; Carbamates; Female; Humans; Melanoma; Protein Kinase Inhibitors; Sulfonamides; Uveomeningoencephalitic Syndrome

2018
Encorafenib plus binimetinib: an embarrassment of riches.
    The Lancet. Oncology, 2018, Volume: 19, Issue:10

    Topics: Benzimidazoles; Carbamates; Embarrassment; Humans; Melanoma; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib

2018
Integrin-targeted quantitative optoacoustic imaging with MRI correlation for monitoring a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma.
    PloS one, 2018, Volume: 13, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cell Line, Tumor; Humans; Integrin alphaVbeta3; Magnetic Resonance Imaging; Melanoma; Mice; Mice, Nude; Molecular Imaging; Mutation; Photoacoustic Techniques; Proto-Oncogene Proteins B-raf; Sulfonamides; Treatment Outcome; Xenograft Model Antitumor Assays

2018
The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:4

    Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Drug Eruptions; Female; Hand-Foot Syndrome; Humans; Keratosis; Male; Melanoma; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides

2019
Evaluation of cutaneous adverse events of encorafenib and binimetinb: COMMENT on article by Graf et al.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:4

    Topics: Benzimidazoles; Carbamates; Fibrosarcoma; Humans; Melanoma; Sulfonamides

2019
Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report.
    Anti-cancer drugs, 2019, Volume: 30, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Drug Resistance, Neoplasm; Humans; Lymph Node Excision; Male; MAP Kinase Kinase 1; Margins of Excision; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib

2019
Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment.
    BMJ case reports, 2019, Sep-16, Volume: 12, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Proto-Oncogene Proteins B-raf; Renal Insufficiency; Skin Neoplasms; Sulfonamides

2019
BEACON of hope in BRAF
    Nature reviews. Clinical oncology, 2019, Volume: 16, Issue:12

    Topics: Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Sulfonamides

2019
Targeted therapy for BRAF-mutant colorectal cancer.
    The Lancet. Oncology, 2019, Volume: 20, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Humans; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome

2019
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
    Cancer, 2020, 02-01, Volume: 126, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Carbamates; Female; Humans; Male; MAP Kinase Kinase Kinases; Melanoma; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides

2020
Clinical and Radiographic Response of Leptomeningeal and Brain Metastases to Encorafenib and Binimetinib in a Patient With BRAF V600E-Mutated Lung Adenocarcinoma.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:12

    Topics: Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Carbamates; Disease Progression; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides

2019
Multiple Pigmented Lesions of the Breast Following Ipsilateral Breast Carcinoma.
    The American journal of medicine, 2020, Volume: 133, Issue:8

    Topics: Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carbamates; Female; Humans; Mastectomy; Mastectomy, Segmental; Melanoma; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Neoplasms, Unknown Primary; Radiotherapy; Skin Neoplasms; Sulfonamides

2020
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
    The New England journal of medicine, 2020, 02-27, Volume: 382, Issue:9

    Topics: Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Sulfonamides

2020
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
    The New England journal of medicine, 2020, 02-27, Volume: 382, Issue:9

    Topics: Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Sulfonamides

2020
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
    The New England journal of medicine, 2020, 02-27, Volume: 382, Issue:9

    Topics: Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Sulfonamides

2020
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Reply.
    The New England journal of medicine, 2020, 02-27, Volume: 382, Issue:9

    Topics: Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Sulfonamides

2020
Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib.
    The Journal of dermatology, 2020, Volume: 47, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Drug Resistance, Neoplasm; Female; Fever; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Nivolumab; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Treatment Outcome

2020
Case of inflammatory arthritis induced by encorafenib and binimetinib in a patient with melanoma.
    The Journal of dermatology, 2020, Volume: 47, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arthritis; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides

2020
Toxic epidermal necrolysis in a melanoma patient under targeted therapy with encorafenib and binimetinib.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2020, Volume: 18, Issue:10

    Topics: Benzimidazoles; Carbamates; Humans; Melanoma; Stevens-Johnson Syndrome; Sulfonamides

2020
Rapid Fluctuation of Subretinal Fluid on Encorafenib and Binimetinib.
    Retina (Philadelphia, Pa.), 2020, Volume: 40, Issue:11

    Topics: Antineoplastic Agents; Astrocytoma; Benzimidazoles; Brain Neoplasms; Carbamates; Female; Humans; MAP Kinase Kinase Kinase 1; MAP Kinase Kinase Kinase 2; Middle Aged; Proto-Oncogene Proteins B-raf; Retinal Diseases; Subretinal Fluid; Sulfonamides

2020
Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass.
    Melanoma research, 2020, Volume: 30, Issue:6

    Topics: Acute Disease; Benzimidazoles; Carbamates; Female; Humans; Melanoma; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Tumor Lysis Syndrome

2020
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.
    Upsala journal of medical sciences, 2020, Volume: 125, Issue:4

    Topics: Antineoplastic Agents; Benzimidazoles; Bevacizumab; CA-125 Antigen; Carbamates; Carboplatin; Cystadenocarcinoma, Serous; Disease Progression; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; MAP Kinase Kinase 1; Medroxyprogesterone; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Oximes; Paclitaxel; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Recurrence; Sulfonamides; Tamoxifen; Treatment Outcome; Young Adult

2020
[New drug approval: Encorafenib-metastatic colorectal cancers with BRAF V600E mutation after systemic chemotherapy].
    Bulletin du cancer, 2020, Volume: 107, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Approval; Humans; Mutation; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Sulfonamides

2020
Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.
    The Journal of dermatology, 2021, Volume: 48, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides

2021
Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.
    British journal of cancer, 2021, Volume: 124, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carbamates; Cetuximab; Cohort Studies; Colorectal Neoplasms; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Retrospective Studies; Sulfonamides; Thiazoles

2021
Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.
    Advances in therapy, 2021, Volume: 38, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Sulfonamides; United States

2021
Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.
    Anti-cancer drugs, 2021, 06-01, Volume: 32, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Communicable Disease Control; COVID-19; Dose-Response Relationship, Drug; Drug Monitoring; Drug Overdose; Humans; Liver Function Tests; Long QT Syndrome; Male; Medication Therapy Management; Melanoma; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vomiting

2021
Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 147

    Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Recovery of Function; Risk Factors; Sulfonamides; Treatment Outcome

2021
[Long-term efficacy of encorafenib plus binimetinib combined treatment: case report.]
    Recenti progressi in medicina, 2021, Volume: 112, Issue:4

    Topics: Aged; Benzimidazoles; Carbamates; COVID-19; Drug Combinations; Female; Humans; Melanoma; Skin Neoplasms; Sulfonamides; Time Factors; Treatment Outcome

2021
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
    Cancer medicine, 2021, Volume: 10, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Carbamates; Carcinoma, Non-Small-Cell Lung; Cardiotoxicity; Cardiovascular Diseases; Colonic Neoplasms; Cross-Sectional Studies; Female; Heart Failure; Humans; Hypertension; Imidazoles; Lung Neoplasms; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Oximes; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Registries; Regression Analysis; Skin Neoplasms; Sulfonamides; Vemurafenib; Venous Thromboembolism; Young Adult

2021
Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib.
    Melanoma research, 2021, 08-01, Volume: 31, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Carbamates; Female; Humans; Melanoma; Proto-Oncogene Proteins B-raf; Radiosurgery; Skin Neoplasms; Sulfonamides

2021
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report.
    Investigational new drugs, 2022, Volume: 40, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Carcinoma, Non-Small-Cell Lung; Colitis; Humans; Lung Neoplasms; Male; Mitogen-Activated Protein Kinase Kinases; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides

2022
Switch from dabrafenib/trametinib combination therapy to encorafenib/binimetinib combination therapy with transition of serum lactate dehydrogenase level in melanoma: A case report.
    Dermatologic therapy, 2022, Volume: 35, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Imidazoles; Lactate Dehydrogenases; Melanoma; Mutation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Neoplasms; Sulfonamides

2022
Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAF
    Clinical colorectal cancer, 2022, Volume: 21, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides

2022
Conjunctival malignant melanoma treated successfully with BRAF inhibitor: encorafenib plus binimetinib.
    Dermatology online journal, 2022, 01-15, Volume: 28, Issue:1

    Topics: Benzimidazoles; Carbamates; Humans; Melanoma; Proto-Oncogene Proteins B-raf; Sulfonamides

2022
[Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report].
    Recenti progressi in medicina, 2022, Volume: 113, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides

2022